Jiangsu Alpha Pharmaceutical Co., Ltd.

Products

(S)-1-Boc-3-hydroxypiperidine

    • Product Name: (S)-1-Boc-3-hydroxypiperidine
    • Chemical Name (IUPAC): (3S)-1-tert-butoxycarbonylpiperidin-3-ol
    • CAS No.: 143900-44-1
    • Chemical Formula: C10H19NO3
    • Form/Physical State: Solid
    • Factroy Site: Yinchuan, Ningxia, China
    • Price Inquiry: sales8@bouling-chem.com
    • Manufacturer: Jiangsu Alpha Pharmaceutical Co., Ltd.
    • CONTACT NOW
    VTB
    Specifications
    HS Code 607694
    Chemical Name (S)-1-Boc-3-hydroxypiperidine
    Alternative Names (S)-tert-Butyl 3-hydroxypiperidine-1-carboxylate
    Cas Number 143900-44-1
    Molecular Formula C10H19NO3
    Molecular Weight 201.26
    Appearance White to off-white solid
    Purity Typically ≥98%
    Melting Point 55-59°C
    Optical Rotation [α]D20 +19° (c=1, CHCl3)
    Solubility Soluble in common organic solvents (e.g., DCM, methanol)
    Storage Conditions Store at 2-8°C, keep container tightly closed
    Smiles CC(C)(C)OC(=O)N1CCC(CO)CC1
    Chirality S-enantiomer
    Use Intermediate in pharmaceutical synthesis

    As an accredited (S)-1-Boc-3-hydroxypiperidine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Brown glass bottle labeled “(S)-1-Boc-3-hydroxypiperidine, 5g,” featuring hazard symbols and supplier information, securely sealed with a screw cap.
    Container Loading (20′ FCL) Container loading (20′ FCL) for (S)-1-Boc-3-hydroxypiperidine involves careful drum packing, palletizing, secure sealing, and compliance with chemical transport regulations.
    Shipping (S)-1-Boc-3-hydroxypiperidine is typically shipped in tightly sealed containers under cool, dry conditions. It is handled according to standard chemical safety protocols, often as a non-hazardous substance. Shipping complies with regulatory guidelines to prevent exposure to moisture and light, ensuring product stability and integrity during transit.
    Storage (S)-1-Boc-3-hydroxypiperidine should be stored in a tightly closed container, kept in a cool, dry, and well-ventilated area, away from direct sunlight and incompatible materials such as strong acids or oxidizers. Store at room temperature (15–25°C). Protect from moisture, as the compound may be sensitive to hydrolysis. Follow relevant safety guidelines and local regulations for chemical storage.
    Shelf Life (S)-1-Boc-3-hydroxypiperidine typically has a shelf life of 2 years when stored in a cool, dry, and tightly sealed container.
    Application of (S)-1-Boc-3-hydroxypiperidine

    Applications of (S)-1-Boc-3-hydroxypiperidine in Industrial Manufacturing

    (S)-1-Boc-3-hydroxypiperidine serves as a specialized intermediate for high-value synthesis in several pharmaceutical and fine chemical manufacturing sectors. Our production integrates this chiral building block under strict quality control, enabling consistent use in advanced downstream processes. Below, key industrial applications are detailed for real-world technical integration.

    1. Active Pharmaceutical Ingredient (API) Synthesis for Central Nervous System (CNS) Drugs

    Manufacturers of CNS-targeted pharmaceuticals use this raw material as a chiral intermediate during the synthesis of specific piperidine-based APIs, such as selective serotonin reuptake inhibitors and antipsychotics. The product enters multi-step synthesis in its protected form, supporting stereoselective reactions that influence drug purity and bioactivity. Production lines rely on batch consistency and regulated handling to maintain compliance with medicinal safety and quality expectations.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Intermediate for Chiral Piperidine-based Oncology Compounds

    Chemical process development teams synthesize specific oncology small molecules using this material as a precursor in asymmetric routes. Its protected hydroxyl position ensures reliable downstream functionalization for anticancer therapeutics, including kinase inhibitors incorporating complex heterocyclic moieties. Multi-kilo campaign production emphasizes traceability and impurity profiling.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Starting Material for Fine Chemical Synthesis in Crop Protection Agents

    The agrochemical sector employs this material to synthesize chiral intermediates for new-generation crop protection molecules such as piperidine-derivative herbicides and insecticides. Control over chiral purity directly affects biological performance and minimizes off-target impacts. Traceability and batch certification are required for regulatory audits and downstream formulation registration.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Chiral Building Block in Contract Development and Manufacturing (CDMO) for Pharma Intermediates

    Contract manufacturing organizations require high-purity, chiral-protected intermediates for bespoke process development supporting major pharmaceutical clients. This compound functions as an entry point for rapid lead molecule generation, often in flow chemistry or automated parallel synthesis settings. Quality assurance procedures track every intermediate batch shipped to customer protocols. Scale-up activities emphasize material reproducibility, including impurity fingerprints for each delivery.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    5. Intermediate for Fine Chemical Synthesis of Advanced Materials

    Chemical engineers use this protected intermediate when tailoring functionalized piperidine derivatives for advanced pharmaceutical excipients or high-performance specialty polymers, leveraging controlled introduction of chiral centers. The material enters unique coupling reactions requiring defined stereochemistry, serving R&D and pilot-scale process validation for customers with high analytical scrutiny.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive (S)-1-Boc-3-hydroxypiperidine prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618005193850

    Email: sales8@bouling-chem.com

    Inquiry

    Get Free Quote of Jiangsu Alpha Pharmaceutical Co., Ltd.

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    (S)-1-Boc-3-hydroxypiperidine: A Manufacturer’s Perspective on Craft, Purity, and the Road to Better Molecules

    Our Journey with (S)-1-Boc-3-hydroxypiperidine

    Years at the reactor bench have taught us certain lessons about chiral intermediates. (S)-1-Boc-3-hydroxypiperidine continues to challenge and impress chemists and engineers alike. From the morning cleaning of glassware to the midnight process checks, every batch connects us to the heart of technical craft and real-world application. The molecule itself seems at first unassuming: a piperidine ring, a Boc protecting group, a single stereocenter on the third carbon, gifting us a rare blend of selectivity and versatility. This isn’t just another niche chemical. Its value shows in the growth of asymmetric synthesis and the rising demand for enantiomerically pure active pharmaceutical ingredients.

    We see the downstream utility of (S)-1-Boc-3-hydroxypiperidine in every pilot run and scale-up we conduct. One of its earlier challenges lay in the inconsistent optical purities reported worldwide—a fact that forced our process development efforts down less-traveled roads. Rather than rely on off-the-shelf chiral resolutions, our route employs an enantioselective synthesis, monitored batch after batch by chiral HPLC. Today, typical lots measure over 99% enantiomeric excess. Customer feedback confirms the difference—a smoother downstream deprotection, fewer headaches with chiral purity at the final step, and most importantly, greater reproducibility in critical synthetic routes.

    Beyond the Number: What the Boc Group Brings

    Protecting groups seem like a detail only a synthetic chemist would sweat over, yet few details influence yield and purity more. With (S)-1-Boc-3-hydroxypiperidine, Boc (tert-butyloxycarbonyl) shielding on the nitrogen prevents side reactions and degradation even after weeks on the shelf. For us, it also means less product lost to hydrolysis, a quieter storage environment, and much less frantic troubleshooting when a shipment arrives at a customer’s facility. Deblocking, while seemingly routine, can turn tricky if small differences in preparation slip by—the reproducible deprotection of our material anchors many customer syntheses. Stocks of unprotected 3-hydroxypiperidine rarely come close in terms of stability or ease of handling. This single protection step makes day-to-day chemistry simpler by a wide margin.

    Our Typical Specifications

    Our standard offering for (S)-1-Boc-3-hydroxypiperidine, identified by the internal model code 3PIP-BS-1117, has a minimum purity of 98% by HPLC, with residual solvent and heavy metals consistently below ICH Q3D thresholds. Moisture levels, measured by Karl Fischer titration, stay within 0.5%. Our QA routine includes regular optical rotation measurements as part of every COA—these are not decorative numbers but practical checkpoints, helping troubleshoot or confirm the integrity of a customer’s multi-step route.

    Batchwise, our volumes typically range from 200 grams at the R&D scale up to multiple kilo lots for commercial projects. We package the compound in airtight HDPE bottles or fluorinated containers, reducing risk of contamination and simplifying ambient shipping. Each batch undergoes repeat NMR, IR, and mass spectrometry checks—these aren’t efforts for the sake of formality, they trace back to recurring requests from med chem clients who need to see the whole data picture for regulatory filings.

    Where (S)-1-Boc-3-hydroxypiperidine Works Hardest

    We watch (S)-1-Boc-3-hydroxypiperidine cross from our hands to those of medicinal and process chemists, most often as a chiral building block for advanced piperidine-based pharmaceuticals. Modern anti-cancer agents, CNS-active drugs, and antiviral candidates all count this intermediate among their early-stage scaffolds. Its protected nitrogen and defined stereochemistry make it easier to introduce diverse sidechains and further derivatizations later in synthesis. Customers report success using it en route to both piperidine-3-ols and piperidine-3-amines, depending on the downstream needs, avoiding the race to resolve racemates in later steps.

    We have supported projects from initial milligram screens to hundred-kilo scale runs. Many clients scaling from R&D to the pilot stage find that various commercial samples differ more than the labels suggest. What looks similar on a specification sheet—a brief list of chemical and physical data—can cause setbacks if small differences aren’t understood. The sources of inconsistency tell stories of their own: lower optical purities leading to fallback plans, unknown impurities appearing mid-route, and difficulties with deprotection under standard conditions. Our tight batch tracking and regular deprotection assay resolve most of these issues early. It means fewer unpleasant surprises at scale for people who rely on what goes into their reactors.

    Real-World Differences: Looking Beyond Purity Labels

    It is easy to see (S)-1-Boc-3-hydroxypiperidine and its racemic or (R)-enantiomeric cousins lumped together on a technical sheet. Yet, even minor lapses in stereo-integrity echo all the way through the downstream products. We have learned that, for some synthetic applications, mixtures as low as 2% wrong enantiomer can dramatically lower yields in chiral catalyst development or complex API synthesis. Our own in-process sampling, dating back nearly eight years, made this reality inescapably clear: a batch with a slip in optical rotation at the second decimal could cost clients weeks in rework, or force revalidation altogether.

    Compared with other piperidine derivatives—like the unprotected 3-hydroxypiperidine, the (R)-enantiomer, and racemic mixtures—our offering brings a reliability that shows not only in purity but in the absence of interfering by-products. For projects where route scouting and optimization matter, we see project managers return for batches that beat standard deviation, reporting fewer chromatographic ghosts and improved NMR profiles. Unprotected analogs commonly degrade faster, fouling both analytical and preparative work. Racemic products may serve in some early screenings but usually fall away as soon as the project moves past the hit-validation phase.

    Choosing the right enantiomer at the right stage means real time and money saved. Downstream, small errors in the starting material can multiply through multi-step reactions, creating the sort of regulatory trouble every manufacturer dreads. For us, every batch sent out is a function not only of chemistry but of cumulative learning from both our own R&D teams and a broad base of customer feedback, helping us refine the critical details batch by batch.

    Our Approach to Consistency

    Time spent on repeat syntheses has taught us how small changes can ripple into much bigger problems. We long ago grew reluctant to cut corners. Every process change, from the order of addition through to the quenching, gets logged in our in-house process book, cross-checked each time we move from the lab to a pilot run. Analytical methods—chiefly chiral HPLC, NMR, and MS—have grown more systematic over the years, not only because regulations demand it, but because in-field troubleshooting often begins with a re-read of the certificate of analysis. Without robust monitoring of optical rotation, or with shortcutting moisture content checks, the downstream synthesis can derail fast.

    Even beyond analysis, handling and storage proved trickier than we once expected. Boc-protected products need careful moisture control, and oxygen exposure can accelerate subtle degradation, especially if transported under humid conditions. Our warehouse controls track ambient temperature and humidity, and the packaging goes through several iterations before landing on the current HDPE drum-and-bag system. Chemists in the field mention better results once these changes went live—fewer clumps, no need for forced drying ahead of critically timed reactions.

    We found value in working directly with end-users during route selection and custom synthesis runs. Some teams working on larger API molecules wanted variants with subtly different impurity profiles or downstream solubility—the result was fine-tuning at the process step and packaging level, unique to each case. This back-and-forth improves reproducibility while minimizing batch-to-batch variability, which is what most R&D and process chemists want: reliability from bulk order to bulk order, not just product “on specification”.

    Industry Challenges: Why Do So Many Batches Fall Short?

    Across the specialty chemical sector, it is common to see batch discrepancies due to differences in process choice, raw material sources, or scale-down issues. Not every producer of (S)-1-Boc-3-hydroxypiperidine gives the same results, even though the literature route seems straightforward. The devil lives in the details—crude intermediates not run through rigorous crude-purity checks, Boc addition steps run at slightly different temperatures, final purification skipped or shortened. These shortcuts amplify as volumes increase, so a seamless gram-scale run can morph into a problematic multi-kilo process given unnoticed impurities, moisture, or scale-induced side-product formation.

    In response, our production flow has grown more granular over time, adding redundant purity checks and implementing final polishing by fractional crystallization or preparative chromatography as needed. Certain projects call for tailoring to a higher HPLC-purity specification, usually for more advanced downstream derivatization. With every new application that reaches out—whether a novel CNS-therapy project, an agrochemical screen, or a contract development pipeline—the fine points of our process adapt to deliver the same familiar product, just at better quality.

    Supporting Industrial and Academic Projects Alike

    Our experience shows that both academic labs pushing new reaction methodologies and small- to mid-sized pharma teams demand consistency and clear, traceable documentation. Client stories help refine our SOPs: for instance, a university group once flagged subtle batch-to-batch differences that showed up only in downstream stereoselective reductions. With their feedback, our in-process chiral controls became stricter, and we began including extra analytical data points with every shipment. In commercial applications, some customers faced trouble when switching between lots or vendors—our solution involved special batch reservation and advanced shipment sampling, so critical production timelines stayed safe.

    We also provide consulting on synthetic applications, from first-time route mapping to troubleshooting problematic scale-ups. Many teams need more than a drum of (S)-1-Boc-3-hydroxypiperidine: they need to know which conditions seem most robust for deprotection, or which downstream transformations perform best given certain traces of side-products. Our in-house chemists regularly share real-time experience on deprotection kinetics, solvent selection, and optimal storage to enhance both shelf-life and working efficiency.

    Quality, Traceability, and the Push for Transparency

    As the regulatory landscape tightens, both for pharmaceuticals and fine chemicals, traceable sourcing and well-documented impurity control count for more than ever. Each outgoing batch carries a lot history, down to supplier-level traceability, QA milestone marking, and stability testing results. Customers increasingly want data transparency across the value chain—they need to follow material identity and quality all the way from primary source to clinical submission. Our batch records reflect not only a chain of custody but a technical lineage, with all deviations logged and investigated before release.

    Transparency has real implications. In a single quarter, customer audits, both remote and in-person, may outnumber all the plant inspections in the previous year. We do not consider these disruptions—they make us sharper, and the feedback translates straight into better recordkeeping and actionable QMS improvements. Traceability also shields project continuity when something unexpected happens, such as a sudden shift in impurity pattern or unforeseen regulatory request. Consistent feedback, both from customer audits and our own QC cycle, informs every improvement.

    Our Thoughts on the Evolving Market

    The landscape for chiral intermediates is changing quickly. Not long ago, few teams asked for tight specs on optical purity or residual solvents. Now, nearly every inquiry requests detailed analytical data—optical rotation, HPLC traces, chiral purity certificates—and expects a quick turnaround. The demand for (S)-1-Boc-3-hydroxypiperidine continues climbing, both for pipeline APIs and for method development in discovery teams. Our job becomes not only about supply but about collaboration: passing along real experience, tuning the product to emerging needs, and catching problems before they grow into bottlenecks.

    The future lies in ever-tighter batch control and feedback-driven improvement. Each customer interaction adds features to the product: better moisture barriers, easier sampling, more detailed documentation, or custom packaging for automated syntheses. As downstream methods evolve, we keep pace, testing new synthetic and analytical tools to ensure the best possible starting material heads out the door, every time.

    Why Experience and Diligence Matter

    Supplying (S)-1-Boc-3-hydroxypiperidine tested our abilities far beyond the initial literature routes. Now, with each new order, the sum of our past troubleshooting transforms daily practice—first in careful training, then in hands-on monitoring and real-time process verification. As more research groups and pharma companies turn to this intermediate for new therapeutic and academic projects, our collective experience becomes a key asset. Years of manufacturing history allow us to offer more than just product—we deliver reliability, deep technical support, and a keen appreciation for the human element running through every step of the process.

    The future of this molecule, and of chiral intermediates at large, grows brighter each time process rigor meets honest feedback, each time documentation aligns with evolving regulatory needs. The pursuit of better, more consistent (S)-1-Boc-3-hydroxypiperidine reflects not only advances in chemical manufacturing but the daily commitment and experience that guide the best batches from lab scale to production floor to the hands of the next chemist in line.